ArticleThe World Allergy Organization journal2026
Clinical characteristics and IgE-binding protein profiles of patients with buckwheat allergy in China.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on "Clinical characteristics and IgE-binding protein profiles of patients with buckwheat allergy in China".The World Allergy Organization journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To characterize patients with buckwheat allergy in China and to investigate the associations between clinical manifestations and different buckwheat IgE-binding proteins. Methods: Patients diagnosed with buckwheat allergy at the Department of Allergy, Peking Union Medical College Hospital, were followed up between 2023 and 2024 and retrospectively enrolled. Serum allergen-specific IgE (sIgE) levels were measured using the ImmunoCAP system, and buckwheat IgE-binding proteins were identified by immunoblotting. Results: A total of 46 patients with buckwheat allergy were included, with a mean age of 26 ± 11 years. 45 patients (97.8%) developed immediate allergic reactions after buckwheat ingestion. Anaphylaxis occurred in 33 patients (73.3%). Seventeen patients (37.0%) experienced respiratory allergic symptoms upon exposure to buckwheat husks. The median f11-sIgE level was 10.75 kUA/L (IQR, 3.01-20.38). Fifteen IgE-binding proteins with different molecular weights were identified, among which the 18-19 kDa protein showed the highest positivity rate (100%). The 14 kDa protein was detected more frequently in patients without anaphylaxis than in those with anaphylaxis induced by buckwheat consumption (25% vs 0%, Conclusion: Patients with buckwheat allergy may present with anaphylaxis, and respiratory symptoms upon exposure to buckwheat husks. Sensitization to the 22-24 kDa protein was associated with concomitant buckwheat husk allergy and higher f11-sIgE levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.